BioLineRx Ltd Cash Flow Conversion Efficiency
BioLineRx Ltd cash flow conversion efficiency. Based on the latest financial reports, BioLineRx Ltd (BLRX) has a cash flow conversion efficiency ratio of -0.196x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.26 Million) by net assets ($16.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BioLineRx Ltd (2008–2025)
Cash flow conversion efficiency of BioLineRx Ltd from 2008 to 2025. This chart illustrates how BioLineRx Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BioLineRx Ltd (BLRX) share price today for real-time trading data and today's change.
BioLineRx Ltd Cash Flow Conversion Ratio Explained
BioLineRx Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BioLineRx Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioLineRx Ltd ranked by their cash flow conversion efficiency. Also see BLRX company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WALLBOX N.V. CL.A EO-12
F:67E
|
N/A |
|
Clinical Laserthermia Systems AB (publ)
ST:CLS-B
|
-0.106x |
|
Landmarks Bhd
KLSE:1643
|
-0.002x |
|
Baselode Energy Corp
V:FIND
|
-0.665x |
|
Bhandari Hosiery Exports Limited
NSE:BHANDARI
|
0.015x |
|
SSH Group Ltd
AU:SSH
|
0.196x |
|
Lease IT Public Company Limited
BK:LIT
|
-0.330x |
|
Tectona
TA:TECT
|
-0.123x |
Annual Cash Flow Conversion Efficiency for BioLineRx Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of BioLineRx Ltd from 2008 to 2025. Review free cash flow generation of BioLineRx Ltd to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $23.34 Million | $-8.14 Million | -0.349x | +89.30% |
| 2024-12-31 | $13.46 Million | $-43.87 Million | -3.259x | -90.63% |
| 2023-12-31 | $13.22 Million | $-22.61 Million | -1.710x | -231.27% |
| 2022-12-31 | $50.84 Million | $-26.24 Million | -0.516x | -49.07% |
| 2021-12-31 | $68.09 Million | $-23.57 Million | -0.346x | +67.13% |
| 2020-12-31 | $22.03 Million | $-23.21 Million | -1.053x | -55.13% |
| 2019-12-31 | $33.38 Million | $-22.67 Million | -0.679x | -15.98% |
| 2018-12-31 | $41.32 Million | $-24.19 Million | -0.585x | -50.68% |
| 2017-12-31 | $52.88 Million | $-20.55 Million | -0.389x | +6.22% |
| 2016-12-31 | $35.03 Million | $-14.51 Million | -0.414x | -39.23% |
| 2015-12-31 | $47.61 Million | $-14.17 Million | -0.298x | +34.72% |
| 2014-12-31 | $31.77 Million | $-14.48 Million | -0.456x | +73.68% |
| 2013-12-31 | $11.68 Million | $-20.23 Million | -1.732x | -28.90% |
| 2012-12-31 | $14.97 Million | $-20.11 Million | -1.344x | -169.77% |
| 2011-12-31 | $22.53 Million | $-11.22 Million | -0.498x | -261.89% |
| 2010-12-31 | $37.26 Million | $11.46 Million | 0.308x | +144.52% |
| 2009-12-31 | $31.13 Million | $-21.51 Million | -0.691x | +48.70% |
| 2008-12-31 | $20.75 Million | $-27.96 Million | -1.347x | -- |
About BioLineRx Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the tr… Read more